Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-06-23Clinical Trial Update: Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) [NA]
A Northwell Health-sponsored clinical trial evaluating biomarkers for diagnosing and assessing pulmonary arterial hypertension has completed…
-
CLINICAL_TRIALS trial_result · 2011-05-27Clinical Trial Update: Biomarkers in the Evaluation of Chronic Lung Disease
A completed clinical trial from Northwell Health evaluating biomarkers for chronic lung diseases, including pulmonary hypertension, pulmonar…
-
CLINICAL_TRIALS trial_result · 2011-05-17Clinical Trial Update: To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension. [Phase 4]
Phase 4 trial updating the efficacy and safety of oral sildenafil for pulmonary arterial hypertension, terminated with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2011-04-19Clinical Trial Update: Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities [Phase 1]
Phase 1 study comparing the bioavailability of treprostinil diethanolamine produced at two independent facilities. The study has completed.
-
CLINICAL_TRIALS trial_result · 2011-04-04Clinical Trial Update: Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
The VENIS trial evaluating Ventavis inhalation therapy for pulmonary arterial hypertension has completed. This update notes the trial status…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-04-01Clinical Trial Update: Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 trial evaluating iloprost inhaled solution as add-on therapy to bosentan in patients with pulmonary arterial hypertension has comple…
-
FDA approval · 2011-03-30FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for VELETRI (epoprostenol) submitted by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2011-03-29FDA Approved: FLOLAN — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for FLOLAN (epoprostenol sodium) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2011-03-03FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc. The approval reflects changes requ…
-
FDA approval · 2011-02-08FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The U.S. FDA approved a supplemental application for REMODULIN (treprostinil) filed by United Therapeutics Corporation.
-
FDA approval · 2011-02-08FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
FDA approved a supplemental application for ADCIRCA (tadalafil) submitted by United Therapeutics Corporation.
-
FDA approval · 2011-02-08FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for TYVASO (treprostinil) submitted by United Therapeutics Corporation. This action represents a…
-
FDA approval · 2011-02-08FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan), authorizing changes to its approved labeling.
-
EMA withdrawal · 2010-12-10Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury
Thelin (sitaxentan) is being withdrawn due to reports of unpredictable serious liver injury.
-
FDA approval · 2010-11-19FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Pfizer Laboratories Division Pfizer Inc.
-
FDA approval · 2010-11-19FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2010-11-19Clinical Trial Update: Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension [Phase 3]
This document reports the completion and posting of results from a Phase 3 safety and efficacy trial of ambrisentan in subjects with pulmona…
-
FDA approval · 2010-10-13FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, updating the labeling for the drug.
-
CLINICAL_TRIALS trial_result · 2010-10-13Clinical Trial Update: A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers [Phase 1]
This Phase 1 study compares the bioavailability of treprostinil diethanolamine oral tablets versus oral solution in healthy volunteers. The …
-
FDA approval · 2010-08-24FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., updating the product’s labeling and/o…
-
FDA approval · 2010-08-23FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for VELETRI (epoprostenol) submitted by Actelion Pharmaceuticals US, Inc. The product is used for tr…
-
CLINICAL_TRIALS trial_result · 2010-08-23Clinical Trial Update: Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine [Phase 1]
Phase 1 pharmacokinetic study evaluating the linearity of exposure and the comparative bioavailability of treprostinil diethanolamine.
-
CLINICAL_TRIALS trial_result · 2010-08-13Clinical Trial Update: The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension [Phase 3]
The Phase 3 'VISION' trial evaluating Ventavis (iloprost) inhalation with sildenafil for pulmonary arterial hypertension was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2010-03-30Clinical Trial Update: To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
Clinical trial update describing sildenafil therapy for eligible adults with pulmonary arterial hypertension over 112 weeks; study status co…
-
CLINICAL_TRIALS trial_result · 2010-03-09Clinical Trial Update: Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans
This document provides an update on a completed clinical trial investigating the relationship between hemodynamics in pulmonary arterial hyp…